**P2551** Late-breaking abstract: When is pleural fluid microbiology useful?  
Kerry Woolsnough, Imran Hussain. Respiratory Medicine, University Hospitals of North Staffordshire, Stoke-on-Trent, United Kingdom

**Introduction:** It is routine clinical practice, and recommended by the British Thoracic Society, that fluid is sent for culture following diagnostic thoracocentesis. Few studies have evaluated the yield from sending all pleural fluid specimens for culture in day to day practice. Culture yield has, however, been studied in cohorts of patients where pleural infection is suspected - with a sensitivity of 54%. We wished to ascertain what our yield is from pleural fluid culture when used as part of a routine workup for an undiagnosed pleural effusion and whether positive cultures were associated with raised inflammatory markers (WCC and CRP).

**Methods:** We retrospectively analysed all pleural fluid samples sent for culture over the previous 12 months. All specimens were cultured for aerobic and anaerobic bacteria, fungi and mycobacterium. Pleural fluid protein, LDH content, serum CRP and WCC were also recorded.

**Results:** 485 samples were sent for culture over the 12 month period. There were 42 (8.7%) positive cultures, of which 4 were excluded as contaminants. 20 different organisms were isolated. Streptococcus anginosus and Mycobacterium tuberculosis were the most common. 47% of these positive samples were exudates, non-transudates. The remainder of these specimens (53%) had no pleural fluid biochemistry performed.

We found a positive yield of 7.8% out of the 485 pleural fluid samples studied. A clear association was found between yield and a raised CRP and WCC with a raised CRP found in 97% of cultures and an increased WCC in 75%.

**Conclusions:** Routine culture of pleural fluid is neither cost-effective nor clinically useful and should only be requested when pleural infection is suspected, both clinically and biochemically.

**P2552** Late-breaking abstract: Inhaled calcium based dry powder inhibits rhinovirus-induced inflammation and exacerbation in a mouse model of allergic airway inflammation  
Psamtzi, R.1,2, Dale Podgorsak, Tim Brogan, Stephen Arzadon, Pamela Okerholm, Faith Saia, Robert Clarke, David Hava. Research, Palmitus Inc., Lexington, MA, United States

Acute exacerbations (AE) in asthma are associated with rhinovirus (Rv) infection. AEs drive disease progression and cause loss of lung function, yet no current therapies target this infectious component. Calcium (Ca) based dry powder (DP) formulations were developed as host-targeted therapies that broadly reduce viral infection in vitro, including Rv. Here, a lead Ca-based DP (PUR118) was tested for efficacy against Rv in a mouse model of infection and AE using Rv1B infection in naïve and ovalbumin (OVA)-challenged mice (Bartlett NW et al Nat Med 2008). Mice (Balb/c) were treated with PUR118 or control DP by whole body exposure, twice daily (BID) 2d prior to Rv infection (5×10³ TCID50) and BID on day of infection. Bronchoalveolar lavage (BAL) inflammation was evaluated 24h post-infection. Additional indices of infection and exacerbation included: viral titers, expression of relevant cytokines and chemokines. Rv infection caused significant neutrophilic inflammation in naïve mice (7.5×10⁵ BAL neutrophils/ml) and exacerbated inflammation in OVA challenged mice (44% increase over control) with increased neutrophils, cytokines and chemokines. In naïve mice, PUR118 treatment reduced neutrophilic inflammation by 38%, which correlated with reduced cytokine and chemokine expression. Similar results were observed in OVA mice where PUR118 treatment reduced neutrophilic inflammation by 40%. The data show Ca-based DP significantly inhibits Rv-induced airway inflammation and Rv-driven exacerbation responses in an asthma-like mouse model. These data support the development of inhaled Ca-based DP to treat infectious causes of AEs in respiratory disease.

**P2555** Antimicrobial resistance genotype trends and association with host clinical characteristics in respiratory isolates of haemophilus influenzae  
Eri Hagwara, Noriko Tsuchiya, Takahiro Enomoto, Tomohisa Baba, Takeshi Shinozuka, Miki Saito, Shigeru Komatsu, Tetsuji Kato, Takashi Ogura, Hiroshi Takahashi. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan

**Objectives:** We aimed to analyze eight-year trend of β-lactam resistance genotype in respiratory isolates of Haemophilus influenzae, and to clarify whether resistance genotypes were correlated with pathogenicity, virulence, and host clinical background.

**Methods:** Respiratory isolates of H. influenzae from 2002 to 2009 in our hospital were classified into gBLNAS: β-lactamase TEM-I negative (BLN) ampicillin susceptible with no resistant genes, gBLNR: BLN ampicillin resistant with two PBPs mutations, and other three genotypes using PCR. 144 strains isolated from different patients in 2008-09 were particularly analyzed for the association between genotypes and host clinical data.

**Results:** Eight-year trend analysis showed the constant decrease of gBLNAS (43% to 30%) along with the steady increase of gBLNR (15% to 53%). Among genotypes the possibility of being causative pathogen was the same in gBLNR 51% and in gBLNAS 49%. There was no significant difference in the levels of C-reactive protein and the white blood cell count in infectious diseases induced by gBLNR and gBLNAS. Host clinical characteristics including age and gender were not different in gBLNR and in gBLNAS except for underlying respiratory diseases. gBLNR was found at the highest rate 92% in isolates from patients with non-tuberculous mycobacteriosis (n=11), followed by 61% from bronchectasis and 55% from chronic bronchitis. In contrast, as low as 33% of isolates from COPD (n=18) were gBLNR.

**Conclusions:** There was no difference in pathogenicity and virulence between gBLNR and gBLNAS in respiratory isolates. Underlying respiratory diseases impacted on the resistance genotype.
P2556
Prior outpatient antibiotic use in patients with community acquired pneumonia (CAP) admitted in hospital
Cristina Sánchez1, Eusebi Chiner2, José Sánchez3, Norberto Sanchez-Chaus4, Ángela Cervera5, Estrella Fernández-Fabrellas5, José Blanquer5, Francisco Sanz5, María del Carmen Aguilar6, Pneumology, Hospital Universitario de Alicante, Spain; 2Pneumology, Hospital Peset, Valencia, Spain; 3Pneumology, Hospital Clínic Valencia, Valencia, Spain; 4Pneumology, Hospital General de Valencia, Valencia, Spain; 5Pneumology, Hospital General de Castellón, Castellón, Spain
Aims: To compare clinical, microbiological, severity and outcomes in patients with CAP admitted to hospital who had received or not previous antibiotic treatment. Method: A 12 months prospective multicenter study was performed in Valencian Community, in Spain (mediterranean area). Factors related comorbidity, etiology, severity, outcomes and mortality, were analyzed. Patients were divided in Group A: antibiotic treatment before admission and Group B: no previous antibiotic treatment.

Results: 1313 CAP, 850 men (65%), 295 in group A (22.4%) with previous antibiotics during 4.3±2.8 days. Patients in group A were younger (59±20 vs 65±18, p<0.001), and more patients treated like outpatients (13.2% vs 8.8%, p<0.05) without differences in residence. When risk factors and comorbidity were analyzed, in group A there were lower proportion of alcohol abuse, heart failure (p<0.05) and CAP evolution days (7.4±4 vs 5.5±4, p<0.001), without differences in other factors. In clinical presentation, group A had more fever and cough (p<0.001), lower dyspnea, and altered mental status (p<0.05), with higher PaO2/FiO2 (293±3.25 vs 281±1.69, p<0.05). No differences in radiology pattern between groups or in etiological confirmation were found. Patients in group A had a lower PSI (81±36 vs 92±35, p<0.001), lower rate of complications (p<0.005) as renal failure, shock, mechanical ventilation and ICU admission (p<0.05), without differences in intrahospital mortality. The length of stay was shorter in group A (9.4±5 vs 11±10 days, p<0.001).

Conclusions: Patients with CAP who received antibiotic treatment before admission were younger, required less hospitalization and the CAP had less severity and complications.

P2557
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobacter baumannii infection
Jung Ar Shin, Hyeong Jung Kim, Min Kwang Byun. Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Background: Acinetobacter baumannii (A. baumannii) has emerged as a major cause of nosocomial pneumonia and sepsis in seriously ill patients. Multidrug-resistant A. baumannii (MRAB) is increasing in frequency, and the management of A. baumannii infections is consequently difficult. Therefore, tigecycline is considered the drug of choice for MRAB treatment. The aim of our study was to evaluate the microbiological eradication and clinical effectiveness of tigecycline against MRAB in seriously ill patients, including patients with ventilator-associated pneumonia (VAP).

Methods: We conducted a retrospective study including patients with A. baumannii infections that were treated with tigecycline between April 1, 2009 and March 31, 2010. We treated 27 patients with tigecycline for MRAB infections.

Results: The mean age of the patients was 66.2 years (44-83 years) and 20 (74.1%) patients were male. The median length of stay was 74.6 days (11-135 days). MRAB was eradicated from the site of infection in 23 cases (85.2%), however only 17 cases (63.0%) showed positive clinical responses. Overall, an inhospital mortality rate of 51.9% was observed and 4 cases of death were attributable to sepsis. The combination therapy group showed better clinical and microbial success rates than the monotherapy group.

Conclusions: We observed successful microbial eradication rates, but clinical success rates were lower than previous studies.

P2558
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefoxime both in combination with clarithromycin in hospitalised patients with community-acquired pneumonia
Arash Etemadi,1,2 Abdolreza Ardeshirzadeh1,3 Mohammad Maaleki2,4 Abbas Chenaneh3,4 Siamak Ahmad1,3 Infectious Disease Department, Ahvaz Jondishapour Medical University, Ahvaz, Khuzestan, Islamic Republic of Iran; 1Internal Medicine Department, Ahvaz Jondishapour Medical University, Ahvaz, Khuzestan, Islamic Republic of Iran; 2Pneumology, Hospital General de Castellón, Castellón, Spain
The objective of the study was to compare the efficacy, safety, and tolerability of Azithromycin (500 mg) intravenously (i.v.) once daily followed by 250 mg orally twice daily for 14 days with Ceftriaxone (2 g) by i.v. infusion twice daily followed by Cefoxime (400 mg) twice daily, both in combination with oral clarithromycin (500 mg) twice daily for the same duration in 63 adult patients initially hospitalized with community-acquired pneumonia. All patients assessed both clinically and bacteriologically one month after the end of the treatment. The results showed statistically significant higher clinical (94.3% vs. 85.4%) and bacteriological success rates (93.7% vs. 81.7%) for patients treated with Azithromycin, irrespective of the severity of the pneumonia. The time to resolution of fever was also faster (median time: 2 vs. 3 days) and hospitalization period was approximately 1 day less for patients who received Azithromycin. The treatment was converted to oral therapy immediately after the initial mandatory 3-day period of i.v. administration for a larger proportion of patients in the Azithromycin group than patients in the control group (50.2% vs. 17.8%). There were fewer deaths (3.0% vs. 5.3%) and fewer serious adverse events (16.5% in the Azithromycin group vs. 16.6% in the control group). The rates of drug-related adverse events were comparable in both groups. Thus, monotherapy with Azithromycin is superior to combination regimen of ceftriaxone plus clarithromycin, in the treatment of community-acquired pneumonia.

P2559
Effectiveness of once daily meropenem for the treatment of aspiration pneumonia of elderly patients in long-term care facilities
Arash Etemadi1, Parviz Salehi1, Khadija Shafiee2, Mehtiar Disease Department, Ahvaz Jondishapour Medical University, Ahvaz, Khuzestan, Islamic Republic of Iran; 2Gerontological Disease Department, Ahvaz Jondishapour Medical University, Ahvaz, Khuzestan, Islamic Republic of Iran
Objective and background: Aspiration pneumonia is a major health problem in residents of long-term care facilities. Antibiotics with broad coverage against gram negative and anaerobic bacteria, such as carbapenems, are cornerstones of treatment. However, once daily administration of meropenem for ambulatory patients is not routine yet.

Methods: A retrospective study of 31 elderly patients with aspiration pneumonia (17 males, 14 females; mean age 85 years) was conducted. In addition, the efficacy and safety of once daily intravenous meropenem (3 g) for the treatment of this condition was evaluated.

Results: The overall detection rate of bacteria was 87% (32 monomicrobial, 55% polymicrobial). gram-negative enteric bacilli and anaerobic bacteria were isolated with the same frequency (20%) The overall clinical efficacy rate of meropenem therapy was 61%. The mortality rate at 10 days was 10%.

Conclusion: The use of antibiotics effective against anaerobic bacteria may be necessary for patients with potentially fatal aspiration pneumonia. Once daily therapy with Meropenem (3 g) for aspiration pneumonia is clinically effective and tolerable in elderly patients.

P2560
Potential protective role of prior diagnosis antibiotic treatment in community-acquired pneumonia: Clinical presentation and outcomes
Francisco Sanz1, Estrella Fernández2, Ana Aguirre3, Carmen Aguilar4, Marisa Brións5, Eusebi Chiner5, Cristina Senent5, José Sánchez5, José Blanquer5,6, Pneumology, Consorci Hospital General Universitari, Valencia, Spain; 2Pneumology, Hospital Dr Peset, Valencia, Spain; 3Pneumology, Hospital Arnau de Vilanova, Valencia, Spain; 4Pneumology, Hospital Clinico Universitari, Valencia, Spain; 5Pneumology, Hospital Clinic Universitari, Valencia, Spain; 6Intensive Care Unit, Hospital Clinic Universitari, Valencia, Spain
Aims: To evaluate the role of prior diagnosis antibiotic therapy in the clinical presentation of community-acquired pneumonia (CAP) and its influence in the outcomes

Methods: CAP’s (excluding HCAP) receiving antibiotic treatment before hospital admission were analyzed. We assessed demographic factors, comorbidities, etiology, and outcomes. Logistic regression analysis was performed to establish causal relationships.

Results: We analyzed 1,197 cases of hospitalized CAP in which 22.6% had a history of prior antibiotic treatment, with a mean duration of 3.9 (2.23) days. Beta lactams were the most frequently used (52.7%) followed by macrolides (29.2%), and quinolones (18.1%). Multivariate analysis showed that patients who received prior antibiotic treatment showed less pneumonia severity on admission (PSI I-III 64.7% vs. 50%, OR 1.81 95% CI 1.64-2.45) and pneumococcal etiological diagnosis was less frequent (13.3% vs. 21.7%, OR 0.61 95% CI 0.41 to 0.92). In patients receiving prior to diagnosis treatment, a shorter hospital stay (8.3±5.1 vs. 10.6±9.7, P=0.001), lower frequency of respiratory failure (21.2% vs. 28.8%, p = 0.023), septic shock (1.5% vs. 4.2%, p = 0.034) and ICU admission (3.3% vs. 6.8%, p = 0.035) were found. No significant differences in mortality were observed.

Conclusions: 1. Prior to diagnosis antibiotic treatment of CAP has a role in modifying the severity of CAP and an impact on pneumococcal etiologic diagnosis. 2. The use of antibiotics before the diagnosis of pneumonia is associated with a shorter hospital stay and less development of complications in our series.

P2561
Antibiotic prescription patterns in hospitalized patients with community-acquired pneumonia in local hospital: 10 year follow-up
Alexander Vizel1, Galina Lysevko1, Photobiophototrial, Kazan Medical University, Kazan, Tatarstan, Russian Federation; 2Standardization and Quality, Ministry of Health of Tatarstan Republic, Kazan, Tatarstan Republic, Russian Federation
Background: In Tatarstan Republic (Russia) regularly update the guidelines of an...
community-acquired pneumonia (CAP) and spend work on updating of knowledge of doctors: lectures, seminars, publications.

**Objective:** We sought to examine patterns of antibiotic prescription during last 10 years in a local hospital. We have estimated prescription of antibiotics at a pneumonia in 2000 (174 cases), 2005 (321) and 2010 (282 cases) years.

**Intervention:** Chart reviews of 777 individual admissions with the diagnosis of pneumonia between January 2000 and December 2010.

**Results:** Compliance with national guidelines for the treatment of CAP increased within 10 years that the table reflects.

Most often applied antibiotics at a community-acquired pneumonia

<table>
<thead>
<tr>
<th>Drug/Year</th>
<th>2000</th>
<th>2005</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin</td>
<td>73%</td>
<td>16.2%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>14.4%</td>
<td>19.0%</td>
<td>13.1%</td>
</tr>
<tr>
<td>Cephalosporin I generation</td>
<td>15.3%</td>
<td>3.4%</td>
<td>0%</td>
</tr>
<tr>
<td>Cephalosporin III generation</td>
<td>4%</td>
<td>58.6%</td>
<td>87.6%</td>
</tr>
<tr>
<td>Macrolides</td>
<td>27%</td>
<td>36.4%</td>
<td>32.0%</td>
</tr>
<tr>
<td>Fluoroquinolones II generation</td>
<td>11.5%</td>
<td>4.7%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Fluoroquinolones III-IV generation</td>
<td>0%</td>
<td>0.3%</td>
<td>16.7%</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>4.0%</td>
<td>0.6%</td>
<td>16.7%</td>
</tr>
<tr>
<td>Sulfamethoxazine</td>
<td>6.9%</td>
<td>0.3%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>0.6%</td>
<td>1.2%</td>
<td>1.1%</td>
</tr>
</tbody>
</table>

Frequency of application III generation cephalosporins has increased about 4% to 87.6%, respiratory fluoroquinolones - about 0% to 16.7%.

**Conclusion:** Research has shown that prescription of antibiotics changed within 10 years. Appointments in 86.7% of cases corresponded to the recommendations accepted in Russia in 2010.

**P2562**

Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment

Fukam Fujihara1, Hamid Reza Jamali2, Payam Tabarsi3, Shadi Bani Asadi4, Somyaeh Ghafar1, Seyed Mohammad Reza Hashemian3, 1 Clinical Pharmacy Department, School of Pharmacy, SRMU, Tehran, Islamic Republic of Iran; 2 Critical Care, Chronic Respiratory Disease Research Center CRDRC/NRRTL, Tehran, Islamic Republic of Iran; 3 Mycobacteriology Research Center, NRRTL, Tehran, Islamic Republic of Iran; 4Pharmaceutical Care Department, TB and Lung Disease Research Center, NRRTL, Tehran, Islamic Republic of Iran

**Introduction:** VAP is the most frequent intensive care unit (ICU) acquired infection. In an effort to improve the clinical outcome, great attention must be given to early and accurate diagnosis, optimal doses of effective antibiotic and best routes of administration.

**Aims and objectives:** The aim of this study was to evaluate the clinical outcome of piperacillin/tazobactam via continuous infusion by serial measurements of Clinical Pulmonary Infection Score (CPIS), compared to intermittent bolus

**Methods:** This study was designed as a prospective clinical trial of continuous infusion or intermittent bolus of a fixed combination of piperacillin/tazobactam and was conducted at the semi-closed intensive care unit of a university hospital. 70 patients were eligible to enter the study. Patients were randomly divided in to two groups and received 3.375 g (piperacillin 3g/tazobactam0.375g) either by intermittent bolus injection every 6 hour in 3-5 min [Intermittent Bolus (IB) group; n=31] or continuous infusion by constant rate of infusion pump every 6 hour in 20-30 min [Continuous Infusion (CI) group; n=39].

**Results:** There were no significant differences in characteristics between the two groups. The mean ±SD age of the patients was 53.8±21.7 years. The APACHE II score was 20.4±6.1 in the CI group and 18.8±5.9 in the IB group (p=0.319). There was a worsening on day 3 compared with the CPIS on day 1, 8.70±2.13 vs 7.04±1.55, and then CPIS showed improvement from day 3. In the CI group more tendency for improvement was observed.

**Conclusion:** This study suggests that the real value of our findings will achieve by determining the concentration-time profiles of piperacillin/tazobactam.

**P2563**

Difference of patient background with pneumonia between monotherapy and combination

Masatake Shibasaki1, Misumi Nishikawa1, Yuichi Kitagawa2, Kazuyoshi Sendai1, Kazumitsu Nakashima1, Fumihiro Mizokami3 1 Respiratory Division, National Center for Geriatrics and Gerontology, Ooba, Aichi, Japan; 2Surgery Division, National Center for Geriatrics and Gerontology, Ooba, Aichi, Japan; 3Pharmacology Division, National Center for Geriatrics and Gerontology, Ooba, Aichi, Japan

**Background:** The current guidelines recommend combination therapy of antibiotics empirically for pneumonia patients with risks of PDR pathogens. However, this recommendation remains controversial. [Aims and objectives] To elucidate factors which may lead physicians to select combination therapy of antibiotics for pneumonia.

**Materials:** Pneumonia patients who were admitted to National Center for Geriatrics and Gerontology Hospital from April 2008 to December 2009, and treated with carbopenem (A group, n=70) or combination of carbopenem-saminoglycosides (B group, n=68).

**Methods:** Information on age, gender, weight, risk factors of PDR pathogens, pneumonia type (CAP/BPCH/AHFAP), Barthel index, clinical response, duration of therapy and 30-day mortality were obtained from chart review. We compared the aforementioned factors between two groups using multiple logistic regression analysis.

**Results:** There were significant differences about the aforementioned factors except age between A and B group in univariate analysis. However, in multivariable logistic regression analysis, only Barthel index was significantly different between both groups (81.8±29.2 in A group vs. 59.1±40.3 in B group, P<0.01, respectively). The clinical efficacy rates were 79% in A and 63% in B groups, respectively. The 30-day mortalities were 13% in A and 38% in B groups, respectively (P<0.067). Duration of antibiotics therapy was significantly shorter in A group compared with B group (7.3±4.7 vs. 19.3±8.2 days, respectively, P<0.01).

**Conclusion:** Barthel index was the independent factor which affected physicians to select combination therapy of antibiotics.

**P2564**

Auditing patterns of azithromycin use in respiratory disease

David Hodgson1, Robert Hurford2, Tim Harrison3, Dominick Shaw1 1Nottingham Respiratory Biomedical Research Unit, University of Nottingham, Nottingham, United Kingdom; 2University of Nottingham Medical School, University of Nottingham, Nottingham, United Kingdom

**Introduction:** In response to increasing use of Azithromycin in respiratory disease we set out to audit local prescribing and clinical outcome.

**Methods:** Data on all Azithromycin prescriptions from a Respiratory Consultant in a large UK teaching hospital between 1st September 2009 and 31st March 2010 were collected. There were 192 prescriptions corresponding to 123 patients. After excluding patients with cystic fibrosis (CF) and Pseudomonas aeruginosa colonisation, 62 sets of notes were reviewed. The subjective clinical benefit of Azithromycin and objective improvement in terms of exacerbations or lung function was assessed.

**Results:** Despite the large variation in phenotypic disease (Figure 1), there was an overall reduction of 0.36 exacerbations per month (P<0.001, 95% CI 0.27-0.46). On further analysis we found that those with evidence of bronchiectasis were significantly more likely to improve after Azithromycin therapy than those without; 88% and 39% respectively (P<0.001).

![Figure 1: Variety of Diseases with Azithromycin Prescriptions](image)

**Conclusions:** Azithromycin is used in a variety of respiratory conditions and we found variable recording of its benefit. A more formal assessment of benefit is required, especially in light of its side effect risk and potential for microbial resistance. Additional randomised controlled trials to further guide treatment are recommended.

**P2565**

PerC antibody prophylaxis in combination with antibiotic therapy reduces lung injury and improves survival in Pseudomonas aeruginosa infected mice

Yuanlin Song1, Mark Baer2, Ramya Sriivnasavan3, Juliana Lima4, Geoffrey Yarranton5, Christopher Bebbington5, Susan Lynch1 1Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai, China; 2KaloBios Pharmaceutical, Inc., KaloBios Pharmaceutical, Inc., San Francisco, CA, United States; 3Gastroenterology, University of California, San Francisco, San Francisco, CA, United States; 4Anesthesia and Perioperative Care, UCSF, San Francisco, CA, United States

The type III secretion system (TTSS) of Pseudomonas aeruginosa facilitates direct injection of cytotoxins into host cell cytoplasm. PeV, located at the tip of the needle-like injectosome, is an essential component of this virulence system. Mab166, a murine monoclonal antibody against PeV has demonstrated efficacy against P. aeruginosa infection resulting in increased survival and reduced lung injury in a variety of mouse models of infection. We hypothesized that administration of Mab166 prophylactically in combination with conventional antibiotics (administered subsequently to infection) could further improve survival of P. aeruginosa infected mice. Three antibiotics (ciprofloxacin, tobramycin and ceftazidime), com-

**Conclusions:** These data suggest that PeV prophylaxis in combination with conventional antibiotics may reduce lung injury and improve survival in P. aeruginosa infected mice, which may have implications for therapeutic strategies for P. aeruginosa infections.
otic administration provides a new strategy against P. aeruginosa airway infection, even heavy burden of highly virulent strains are present and may represent a viable prophylactic approach for patients at high risk for P. aeruginosa infection.

**P2566**  
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia?

Sonia Seghezzi¹, Marta Di Pasquale², Stefano Albetti², Giulia Marullo¹, Valer Monzani³, Anna Maria Brambilla¹, Roberto Cosentini¹, ¹, ²U.O. Medicina d’Urgenza, Fondazione IRCCS Cà Grande Ospedale Maggiore Policlinico, Milan, Italy; ²U.O. Broncopediatria, Fondazione IRCCS Cà Grande Ospedale Maggiore Policlinico, Milan, Italy; ³U.O. Broncopediatria, Ospedale S. Gerardo, Monza, Italy

Pneumonia caused by MDR pathogens is becoming a worldwide problem difficult to manage. The aim was to investigate whether in pneumonia MDR infection is associated with acute respiratory failure (ARF) development or with a higher mortality.

We retrospectively investigated patients with CAP or RACAP who had been admitted to Fondazione IRCCS Cà Grande Policlinico of Milan from January 2008 to April 2010. We considered as MDR the following ones: MRSA, ESBL bacteria, multiresistant Pseudomonas, Vancomycin-resistant Enterococcus and Acinetobacter baumannii.

935 patients with pneumonia (504 males) with a mean age of 76±14, were included in the study. One or more pathogens were isolated in 183 cases (20%) and MDR was found in 28 (3%). Factors that most likely were associated to a MDR infection were a previous hospitalization (odds ratio 5; 95% CI 2.1-11.8) and antibiotic treatment (OR 2.48; 95% CI 1.008-6.1) within 90 days. MDR infection was associated with a higher mortality (p 0.001), OR 5; 95% CI 2.11-11.8) but not with ARF development (p 0.093). Clinical features on admission are listed in table 1.

<table>
<thead>
<tr>
<th>Age</th>
<th>PSI</th>
<th>COPD</th>
<th>Immuno depression</th>
<th>PaO2/FiO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>73±15</td>
<td>119±40</td>
<td>39(25)</td>
<td>59(17)</td>
<td>265±76</td>
</tr>
<tr>
<td>84±7</td>
<td>144±40</td>
<td>12(42)</td>
<td>11(39)</td>
<td>228±52</td>
</tr>
<tr>
<td>0.0001</td>
<td>0.004</td>
<td>0.052</td>
<td>0.883</td>
<td>0.030</td>
</tr>
</tbody>
</table>

A multivariable regression logistic analysis adjusted for immune system status and empiric antibiotic coverage of aetiological pathogen showed that MDR infection was an independent risk factor for mortality (OR 7.5; 95% CI 1.75-32). These results suggest that, despite a correct initial antibiotic treatment, a MDR infection seem related to a poor outcome so this subgroup of patients should be closely monitored and treated with aggressive support measures.

**P2567**  
Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial

Dominic Snijders¹, Casper de Graaff¹, Tjip van der Werf², Wim Boersma¹.

¹Department of Pulmonary Medicine, Medical Centre Alkmaar, Alkmaar, Netherlands; ²Departments of Internal Medicine, and Pulmonary Diseases & Tuberculosis, University Medical Center Groningen, Groningen, Netherlands

The aim of this study was to evaluate the use of antibiotics according to the Dutch guideline in patients with CAP included in a clinical trial with respect to clinical outcome at day 30. Antibiotic therapy was based on severity scoring of CAP next to clinical judgment.

A total of 213 patients were evaluated. Amoxicillin (122 patients, 57.3%) was most often prescribed (CURB-65 0-2: 82.8%; CURB-65 3-5: 17.2%), followed by moxifloxacin (80 patients, 37.6%) (CURB-65 0-2: 61.3%; CURB-65 3-5: 38.8%) and amoxicillin/clavulanic acid (9 patients, 4.2%) (CURB-65 0-2: 77.8%; CURB-65 3-5: 22.2%). 30 day mortality was 12 (5.6%) patients, 4 patients on initial amoxicillin and 8 patients on initial moxifloxacin. Patients on amoxicillin had a clinical success rate at day 30 of 80.0%, while patients on moxifloxacin had a clinical success rate of 63.3%.

In 20 (9.4%) patients antibiotic treatment was narrowed, whereas 7 (3.3%) patients were treated with broader spectrum antibiotics; 186 (87.3%) patients remained on their initial antibiotics.

In a multivariate analysis only severe CAP (CURB-65 score >2) was associated with clinical failure at day 30 (OR 6.0, 95% CI 2.1-17.5), while type of antibiotics, antibiotic change (narrowing of broadening) and aetiology were not associated with treatment failure.

Conclusion: Patients with non-severe CAP can safely be treated with amoxicillin. The use of Dutch guideline concordant antibiotics resulted in a low rate of broadening antibiotic treatment. Antibiotic therapy was not associated in multivariate analysis with clinical outcome at day 30.

Table 1. Clinical features on admission

<table>
<thead>
<tr>
<th>Age</th>
<th>PSI</th>
<th>COPD</th>
<th>Immuno depression</th>
<th>PaO2/FiO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>73±15</td>
<td>119±40</td>
<td>39(25)</td>
<td>59(17)</td>
<td>265±76</td>
</tr>
<tr>
<td>84±7</td>
<td>144±40</td>
<td>12(42)</td>
<td>11(39)</td>
<td>228±52</td>
</tr>
<tr>
<td>0.0001</td>
<td>0.004</td>
<td>0.052</td>
<td>0.883</td>
<td>0.030</td>
</tr>
</tbody>
</table>

**P2568**  
Effect of benzylpenicillin-ciprofloxacin vs. ceftriaxone-ciprofloxacin in treatment of massive pneumonia (CAP-community acquired pneumonia)

Vojislav Radosavljevic, Milica Obrovac, Natasa Petrovic. Palmolog, KBC Bezanjska Kosa, Belgrade, Serbia. Palmolog, KBC Bezanjska Kosa, Belgrade, Serbia

In the past few years a high level of massive pneumonia has been noticed. The aim of study was to compare the effect of benzylpenicillin-ciprofloxacin versus ceftriaxone-ciprofloxacin in treatment of massive pneumonia.

Material and methods: There were 60 patients (male-34,female-26;22-68 years old) who were divided in two groups according to the therapeutic treatment. All patients had radiological image of lobar massive CAP with biochemical verificataion, and pneumonia score between 70-90. The first group with thirty patients was treated with a combination of benzylpenicillin (1.6 million i.m per day)+ ciprofloxacin (500mgx2 p.o. per day) for seven days. The second group with also thirty patients was treated with a combination of ceftriaxone (2g per day)+ ciprofloxacin (500mgx2) also for seven days. After the treatment we compared radiological image according to RECIST criteria.

Results: In the first group were 14 with complete, 10 with partial, 2 with stable response and 4 with progression of disease. In the second group there were 16 with complete, 7 with partial, 4 with stable response and 3 with progression of disease. There were no deaths and no complications during the treatment. There was no statistical significance between the two groups of patients in treatment of massive pneumonia (CAP-Community acquired pneumonia) p>0.05.

Conclusion: According to our result we can conclude that the combination of benzylpenicillin-ciprofloxacin has given good results in treatment of massive lobar pneumonia (CAP) with good safety and tolerance. Costs benefit recommends benzylpenicillin-ciprofloxacin for therapy of choice.